Manufacturer
MALAYSIAN PHARMACEUTICAL INDUSTRIES SDN. BHD.
Contents
Olanzapine
Indication
Acute mixed or manic episodes in bipolar disorder and Schizophrenia.
Instruction
May be taken with or without food.
Drug interaction
Increased olanzapine clearance w/ CYP1A2 inducers (e.g. carbamazepine, omeprazole). Inhibits metabolism w/ CYP1A2 inhibitors (e.g. fluvoxamine). May antagonise effects of levodopa and dopamine agonists. Reduced bioavailability w/ activated charcoal. Additive effect w/ centrally acting drugs or drugs known to increase QT interval.
Malaysia
